Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease

Experimental Neurology

Volumn 209, Issue 1, 2008, Pages 213-223

  Ebert, Allison D ^a   Beres, Amy J ^a   Barber, Amelia E ^a   Svendsen, Clive N ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

6 Hydroxydopamine; GDNF; Gene therapy; Lentivirus; Stem cells

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; SOMATOMEDIN C; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL REGENERATION; CELL SURVIVAL; CELL TRANSPLANTATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; HUMAN NEURAL PROGENITOR CELL; IMMUNOHISTOCHEMISTRY; NERVE DEGENERATION; NERVE FUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PREVENTION; PRIORITY JOURNAL; RAT; STEM CELL;

AMPHETAMINE; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM STIMULANTS; DATA INTERPRETATION, STATISTICAL; DOPAMINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; LENTIVIRUS; MALE; NERVE FIBERS; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, INBRED LEW; STEM CELL TRANSPLANTATION; STEM CELLS; STEREOTYPED BEHAVIOR; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

EID: 37549042851     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.09.022     Document Type: Article

References (51)

1. Akerud P., Alberch J., Eketjall S., Wagner J., and Arenas E. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. J. Neurochem. 733 (1999) 70-78
2. Arsenijevic Y., Weiss S., Schneider B., and Aebischer P. Insulin-like growth factor-I is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2. J. Neurosci. 21 (2001) 7194-7202
3. Bakshi A., Shimizu S., Keck C.A., Cho S., Lebold D.G., Morales D., Arenas E., Snyder E.Y., Watson D.J., and McIntosh T.K. Neural progenitor cells engineered to secrete GDNF show enhanced survival, neuronal differentiation and improve cognitive function following traumatic brain injury. Eur. J. Neurosci. 23 (2006) 2119-2134
4. Behrstock S., Ebert A., McHugh J., Vosberg S., Moore J., Schneider B., Capowski E., Hei D., Kordower J., Aebischer P., and Svendsen C.N. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther. 13 (2006) 379-388
5. Bilak M.M., and Kuncl R.W. Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons. NeuroReport 12 (2001) 2531-2535
6. Bilak M.M., Corse A.M., and Kuncl R.W. Additivity and potentiation of IGF-I and GDNF in the complete rescue of postnatal motor neurons. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2 (2001) 83-91
7. Bjorklund A., Kirik D., Rosenblad C., Georgievska B., Lundberg C., and Mandel R.J. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886 (2000) 82-98
8. Bjugstad K.B., Redmond D.E., Teng Y.D., Elsworth J.D., Roth R.H., Blanchard B.C., Snyder E.Y., and Sladek J.R. Neural stem cells implanted into MPTP-treated monkeys increase the size of endogenous tyrosine hydroxylase-positive cells found in the striatum: a return to control measures. Cell Transplant 14 (2005) 183-192
9. Bondy C.A., and Cheng C.M. Signaling by insulin-like growth factor 1 in brain. Eur. J. Pharmacol. 490 (2004) 25-31
10. Burnstein R.M., Foltynie T., He X., Menon D.K., Svendsen C.N., and Caldwell M.A. Differentiation and migration of long term expanded human neural progenitors in a partial lesion model of Parkinson's disease. Int. J. Biochem. Cell Biol. 36 (2004) 702-713
11. Cao Y., Gunn A.J., Bennet L., Wu D., George S., Gluckman P.D., Shao X.M., and Guan J. Insulin-like growth factor (IGF)-1 suppresses oligodendrocyte caspase-3 activation and increases glial proliferation after ischemia in near-term fetal sheep. J. Cereb. Blood Flow Metab. 23 (2003) 739-747
12. Capowski E.E., Schneider B.L., Ebert A.D., Seehus C.R., Szulc J., Zufferey R., Aebischer P., and Svendsen C.N. Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy. J. Neurosci. Methods 163 (2007) 338-349
13. Castano A., Herrera A.J., Cano J., and Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 70 (1998) 1584-1592
14. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., and Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275 (1997) 838-841
15. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., and Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 15 (2002) 991-998
16. Creedon D.J., Tansey M.G., Baloh R.H., Osborne P.A., Lampe P.A., Fahrner T.J., Heuckeroth R.O., Milbrandt J., and Johnson Jr. E.M. Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 7018-7023
17. Deglon N., Tseng J.L., Bensadoun J.C., Zurn A.D., Arsenijevic Y., Pereira d.A., Zufferey R., Trono D., and Aebischer P. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 11 (2000) 179-190
18. Donsante A., Miller D.G., Li Y., Vogler C., Brunt E.M., Russell D.W., and Sands M.S. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317 (2007) 477
19. Gash D.M., Zhang Z.M., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., and Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380 (1996) 252-255
20. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., and Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9 (2003) 589-595
21. Guan J., Krishnamurthi R., Waldvogel H.J., Faull R.L., Clark R., and Gluckman P. N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Res. 859 (2000) 286-292
22. Guan J., Bennet L., George S., Wu D., Waldvogel H.J., Gluckman P.D., Faull R.L., Crosier P.S., and Gunn A.J. Insulin-like growth factor-1 reduces postischemic white matter injury in fetal sheep. J. Cereb. Blood Flow Metab. 21 (2001) 493-502
23. Hsich G., Sena-Esteves M., and Breakefield X.O. Critical issues in gene therapy for neurologic disease. Hum. Gene Ther. 13 (2002) 579-604
24. Hughes R.A., Sendtner M., and Thoenen H. Members of several gene families influence survival of rat motoneurons in vitro and in vivo. J. Neurosci. Res. 36 (1993) 663-671
25. Imitola J., Raddassi K., Park K.I., Mueller F.J., Nieto M., Teng Y.D., Frenkel D., Li J., Sidman R.L., Walsh C.A., Snyder E.Y., and Khoury S.J. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 18117-18122
26. Isacson O., and Deacon T.W. Specific axon guidance factors persist in the adult brain as demonstrated by pig neuroblasts transplanted to the rat. Neurosci 75 (1996) 827-837
27. Jones D.M., Tucker B.A., Rahimtula M., and Mearow K.M. The synergistic effects of NGF and IGF-1 on neurite growth in adult sensory neurons: convergence on the PI 3-kinase signaling pathway. J. Neurochem. 86 (2003) 1116-1128
28. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., and Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301 (2003) 839-842
29. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 (1998) 259-277
30. Klein S.M., Behrstock S., McHugh J., Hoffmann K., Wallace K., Suzuki M., Aebischer P., and Svendsen C.N. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum. Gene Ther. 16 (2005) 509-521
31. Kordower J.H. In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann. Neurol. 53 Suppl 3 (2003) S120-S132
32. Kordower J.H., Palfi S., Chen E.Y., Ma S.Y., Sendera T., Cochran E.J., Mufson E.J., Penn R., Goetz C.G., and Comella C.D. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46 (1999) 419-424
33. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., and Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
34. Krishnamurthi R., Stott S., Maingay M., Faull R.L., McCarthy D., Gluckman P., and Guan J. N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats. NeuroReport 15 (2004) 1601-1604
35. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., and Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59 (2006) 459-466
36. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
37. McBride J.L., Behrstock S.P., Chen E.Y., Jakel R.J., Siegel I., Svendsen C.N., and Kordower J.H. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J. Comp. Neurol. 475 (2004) 211-219
38. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
39. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws Jr. E.R., Lozano A.M., Penn R.D., Simpson Jr. R.K., Stacy M., and Wooten G.F. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60 (2003) 69-73
40. Ostenfeld T., Caldwell M.A., Prowse K.R., Linskens M.H., Jauniaux E., and Svendsen C.N. Human neural precursor cells express low levels of telomerase in vitro and show diminishing cell proliferation with extensive axonal outgrowth following transplantation. Exp. Neurol. 164 (2000) 215-226
41. Ourednik J., Ourednik V., Lynch W.P., Schachner M., and Snyder E.Y. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat. Biotechnol. 20 (2002) 1103-1110
42. Quesada A., and Micevych P.E. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions. J. Neurosci. Res. 75 (2004) 107-116
43. Redmond Jr. D.E., Bjugstad K.B., Teng Y.D., Ourednik V., Ourednik J., Wakeman D.R., Parsons X.H., Gonzalez R., Blanchard B.C., Kim S.U., Gu Z., Lipton S.A., Markakis E.A., Roth R.H., Elsworth J.D., Sladek Jr. J.R., Sidman R.L., and Snyder E.Y. Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells. Proc. Nat. Acad. Sci. U. S. A. 104 (2007) 12175-12180
44. Sherer T.B., Fiske B.K., Svendsen C.N., Lang A.E., and Langston J.W. Crossroads in GDNF therapy for Parkinson's disease. Mov. Disord. 21 (2006) 136-141
45. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., and Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102 (2005) 216-222
46. Suzuki M., McHugh J., Tork C., Shelley B., Klein S.M., Aebischer P., and Svendsen C.N. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE 8 (2007) e689
47. Svendsen C. The first steps towards gene therapy for Parkinson's disease. Lancet Neurol. 6 (2007) 754-756
48. Svendsen C.N., and Langston J.W. Stem cells for Parkinson disease and ALS: replacement or protection?. Nat. Med. 10 (2004) 224-225
49. Svendsen C.N., ter Borg M.G., Armstrong R.J., Rosser A.E., Chandran S., Ostenfeld T., and Caldwell M.A. A new method for the rapid and long term growth of human neural precursor cells. J. Neurosci. Methods 85 (1998) 141-152
50. Tolbert D.L., and Clark B.R. GDNF and IGF-I trophic factors delay hereditary Purkinje cell degeneration and the progression of gait ataxia. Exp. Neurol. 183 (2003) 205-219
51. Yan Y.P., Sailor K.A., Vemuganti R., and Dempsey R.J. Insulin-like growth factor-1 is an endogenous mediator of focal ischemia-induced neural progenitor proliferation. Eur. J. Neurosci. 24 (2006) 45-54